NASDAQ:AUPH - Aurinia Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.60
  • Forecasted Upside: 125.35 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.05 (0.44%)

This chart shows the closing price for AUPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aurinia Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AUPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AUPH

Analyst Price Target is $25.60
▲ +125.35% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is $25.60, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 125.35% upside from the last price of $11.36.

This chart shows the closing price for AUPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Aurinia Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/4/2022HC WainwrightLower Price Target$33.00 ➝ $30.00High
4/28/2022Cantor FitzgeraldReiterated RatingOverweightHigh
4/28/2022Royal Bank of CanadaLower Price TargetOutperform$27.00 ➝ $22.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/8/2022SVB LeerinkLower Price TargetOutperform$30.00 ➝ $22.00High
3/1/2022HC WainwrightReiterated RatingBuy$40.00 ➝ $33.00Low
3/1/2022Royal Bank of CanadaLower Price TargetOutperform$31.00 ➝ $27.00Medium
2/23/2022Royal Bank of CanadaLower Price TargetOutperform$34.00 ➝ $31.00High
12/15/2021Jefferies Financial GroupReiterated RatingBuyHigh
12/10/2021OppenheimerUpgradeMarket Perform ➝ Outperform$33.00 ➝ $31.00High
11/4/2021OppenheimerBoost Price TargetMarket Perform$32.00 ➝ $33.00Low
11/4/2021HC WainwrightBoost Price TargetBuy$35.00 ➝ $40.00Medium
11/4/2021SVB LeerinkBoost Price TargetOutperform$28.00 ➝ $35.00Medium
10/28/2021OppenheimerDowngradeOutperform ➝ Market Perform$28.00 ➝ $32.00Medium
10/26/2021Royal Bank of CanadaBoost Price TargetOutperform$23.00 ➝ $34.00High
10/1/2021Bloom BurtonInitiated CoverageHold$23.00Medium
8/19/2021SVB LeerinkReiterated RatingBuyLow
5/7/2021Bloom BurtonUpgradeAccumulate ➝ BuyHigh
5/7/2021Royal Bank of CanadaLower Price TargetOutperform$26.00 ➝ $23.00Medium
5/7/2021OppenheimerReiterated RatingBuyHigh
4/11/2021SVB LeerinkReiterated RatingBuyMedium
2/25/2021Royal Bank of CanadaLower Price TargetOutperform$28.00 ➝ $26.00Low
1/27/2021SVB LeerinkBoost Price TargetOutperform$24.00 ➝ $28.00High
1/26/2021Royal Bank of CanadaBoost Price TargetAverage ➝ Outperform$20.00 ➝ $28.00High
1/26/2021Cantor FitzgeraldBoost Price TargetOverweight$27.00 ➝ $34.00High
1/25/2021OppenheimerBoost Price Target$20.00 ➝ $28.00High
1/25/2021HC WainwrightBoost Price TargetBuy$30.00 ➝ $35.00High
12/18/2020HC WainwrightBoost Price TargetBuy$28.00 ➝ $30.00Medium
12/17/2020OppenheimerReiterated RatingBuy$20.00Medium
11/12/2020Cantor FitzgeraldLower Price Target$30.00 ➝ $26.00Low
11/3/2020Bloom BurtonDowngradeBuy ➝ AccumulateLow
11/3/2020HC WainwrightLower Price TargetBuy$34.00 ➝ $28.00Medium
8/13/2020Royal Bank of CanadaReiterated RatingBuyLow
8/12/2020HC WainwrightBoost Price TargetBuy$33.00 ➝ $34.00Low
7/22/2020HC WainwrightBoost Price TargetBuy$32.00 ➝ $33.00Medium
6/16/2020BTIG ResearchInitiated CoverageBuy$20.00Low
5/17/2020Royal Bank of CanadaReiterated RatingBuy$20.00Low
5/14/2020OppenheimerInitiated CoverageBuy$22.00Low
5/5/2020CowenInitiated CoverageOutperformHigh
4/20/2020HC WainwrightReiterated RatingBuy$32.00High
3/19/2020Bloom BurtonReiterated RatingBuy$23.00Low
3/9/2020Royal Bank of CanadaReiterated RatingBuyMedium
3/6/2020Cantor FitzgeraldBoost Price TargetOverweight$30.00 ➝ $32.00High
1/10/2020Jefferies Financial GroupInitiated CoverageBuy$27.00Medium
12/16/2019HC WainwrightBoost Price TargetBuy$25.00 ➝ $32.00Low
12/5/2019Cantor FitzgeraldBoost Price Target$24.00 ➝ $30.00Low
12/5/2019OppenheimerBoost Price Target$14.00 ➝ $22.00Low
12/5/2019Royal Bank of CanadaBoost Price TargetOutperform$11.00 ➝ $20.00N/A
11/1/2019HC WainwrightSet Price TargetBuy$25.00Low
10/17/2019Cantor FitzgeraldReiterated RatingOverweightLow
10/2/2019Bloom BurtonReiterated RatingBuyLow
9/10/2019OppenheimerInitiated CoverageOutperform$14.00 ➝ $14.00High
9/9/2019CitigroupInitiated CoverageOutperform$14.00High
8/8/2019Royal Bank of CanadaReiterated RatingBuy$11.00Medium
6/4/2019HC WainwrightReiterated RatingBuy$25.00Low
5/23/2019HC WainwrightReiterated RatingBuy$15.00 ➝ $25.00Medium
5/15/2019HC WainwrightReiterated RatingBuyHigh
3/20/2019Raymond JamesBoost Price TargetOutperform$9.00 ➝ $11.00High
3/20/2019Royal Bank of CanadaBoost Price TargetOutperform ➝ Positive$9.00 ➝ $11.00High
3/19/2019Cantor FitzgeraldReiterated RatingBuy$18.00 ➝ $24.00High
10/1/2018Cantor FitzgeraldSet Price TargetBuy$18.00Medium
9/26/2018HC WainwrightReiterated RatingBuy$15.00Low
9/25/2018Cantor FitzgeraldSet Price TargetBuy$18.00Medium
8/13/2018HC WainwrightBoost Price TargetBuy$15.00High
8/11/2018Cantor FitzgeraldSet Price TargetBuy$18.00High
7/11/2018Cantor FitzgeraldSet Price TargetBuy$16.00High
5/16/2018Cantor FitzgeraldSet Price TargetBuy$16.00Medium
5/10/2018Cantor FitzgeraldReiterated RatingBuy$16.00High
5/2/2018HC WainwrightReiterated RatingBuy$12.00Low
3/15/2018Cantor FitzgeraldSet Price TargetOverweight ➝ Overweight$14.00 ➝ $16.00High
2/8/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$9.00Medium
11/15/2017HC WainwrightReiterated RatingBuy$12.00N/A
10/30/2017HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $12.00N/A
10/23/2017SVB LeerinkBoost Price TargetOutperform$10.00 ➝ $14.00N/A
10/23/2017Cantor FitzgeraldReiterated RatingBuy$14.00N/A
8/11/2017Cantor FitzgeraldSet Price TargetBuy$14.00High
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 23 positive mentions
  • 8 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 3 very positive mentions
  • 23 positive mentions
  • 8 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Read More

Today's Range

Now: $11.36
Low: $11.07
High: $11.57

50 Day Range

MA: $11.51
Low: $8.95
High: $12.80

52 Week Range

Now: $11.36
Low: $8.86
High: $33.97


751,299 shs

Average Volume

2,869,602 shs

Market Capitalization

$1.61 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Aurinia Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Aurinia Pharmaceuticals in the last twelve months: Bloom Burton, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Royal Bank of Canada,, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for AUPH.

What is the current price target for Aurinia Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Aurinia Pharmaceuticals in the last year. Their average twelve-month price target is $25.60, suggesting a possible upside of 126.3%.
View the latest price targets for AUPH.

What is the current consensus analyst rating for Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AUPH will outperform the market and that investors should add to their positions of Aurinia Pharmaceuticals.
View the latest ratings for AUPH.

How do I contact Aurinia Pharmaceuticals' investor relations team?

Aurinia Pharmaceuticals' physical mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company's listed phone number is 250-708-4272 and its investor relations email address is [email protected] The official website for Aurinia Pharmaceuticals is Learn More about contacing Aurinia Pharmaceuticals investor relations.